ArticleInternational journal of clinical and experimental pathology2017
SIRT4 is upregulated in breast cancer and promotes the proliferation, migration and invasion of breast cancer cells.
Article in International journal of clinical and experimental pathology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 16 citations in OpenAlex.
- Sirtuin 4 is downregulated in oral carcinogenesis.Odontology · 2026Article
- SIRT4 is associated with microvascular infiltration, immune cell infiltration, and epithelial mesenchymal transition in hepatocellular carcinoma.Histology and histopathology · 2025Article
- SIRT4 Controls Acetyl-CoA Synthesis to Promote Stemness and Invasiveness of Hepatocellular Carcinoma through Deacetylating MCCC2.International journal of biological sciences · 2025Article
- Sirtuins and tumor immunity: mechanistic insights, immunotherapy prospects, and therapeutic horizons.Frontiers in immunology · 2025Review
- Decreased sirtuin 4 levels promote cellular proliferation and invasion in papillary thyroid carcinoma.European thyroid journal · 2024Article
- The dual role of sirtuins in cancer: biological functions and implications.Frontiers in oncology · 2024Review
- Mitochondrial Sirtuins in Cancer: A Revisited Review from Molecular Mechanisms to Therapeutic Strategies.Theranostics · 2024Review
- Review
- Circular RNA OMA1 regulates the progression of breast cancer via modulation of the miR‑1276/SIRT4 axis.Molecular medicine reports · 2021Article
- Mitochondrial Tumor Suppressors-The Energetic Enemies of Tumor Progression.Cancer research · 2021Review
- VHL regulates the sensitivity of clear cell renal cell carcinoma to SIRT4-mediated metabolic stress via HIF-1α/HO-1 pathway.Cell death & disease · 2021Article
- Review
- SIRT4 and SIRT6 Serve as Novel Prognostic Biomarkers With Competitive Functions in Serous Ovarian Cancer.Frontiers in genetics · 2021Article
- The sirtuin family in cancer.Cell cycle (Georgetown, Tex.) · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSeveral members of the SIRT family (SIRT1-7), a highly conserved family of NAD
methodsWe investigated SIRT4 protein levels in breast cancer and its possible association with selected clinicopathological parameters by immunohistochemical staining of a tissue microarray that included samples from 94 breast cancer patients. We further invested the effect of SIRT4 on the proliferation, migration and invasion of breast cancer cells.
resultsSIRT4 protein levels in breast were markedly higherthan their non-neoplastic tissue counterparts (P<0.001). Additionally, SIRT4 promoted the proliferation, migration and invasion of breast cancer cells.
conclusionsOur results show that SIRT4 possess oncogenic properties at the human cancer cell level and indicate that SIRT4 may participate in the development of breast cancer.
Indexed as
Identifiers
31966549PMC6966060W3014234973What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.